Merseyside Inter Agency Drug Misuse Database

January - March 2010

Warrington DAT

Quarter 4 2009/10

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
4th Floor, Kingsway House
Hatton Gardens
Liverpool
L3 2AY

(0151) 904 6031
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 8014
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS) 17

Combined Datasets 20

Cross Matched Datasets 21

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

> Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2009/10)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	29	90.6
Female	3	9.4
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	9	28.1
25-29	6	18.8
30-34	3	9.4
35-39	9	28.1
40-44	5	15.6
45+	0	0.0
Total	32	100

Table 2: Year to Date, by Gender & Age Group

	Gender				*Total in Age Group*	
	Male		Female			
Age Group	n	%	n	%	*n*	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	1.1	0	0.0	1	<1
20-24	20	21.7	1	5.6	21	19.1
25-29	17	18.5	1	5.6	18	16.4
30-34	18	19.6	8	44.4	26	23.6
35-39	21	22.8	4	22.2	25	22.7
40-44	12	13.0	3	16.7	15	13.6
45+	3	3.3	1	5.6	4	3.6
Total	92	100	18	100	110	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	-	-	-
Benzodiazepines	1	0	0
Cannabis	5	0	0
Crack	-	-	-
Cocaine	0	1	0
Ecstasy	-	-	-
Heroin	22	1	0
Methadone	2	0	0
Subutex	-	-	-
Other	-	-	-

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

Fig 1: Crossover between DIP Individuals and NDTMS Datasets

PROBATION
Quarter 4 (2009/10)

Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

NOTE: Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

Table 4: Probation Clients by Gender and Age Group

Gender	n	%
Male	62	84.9
Female	11	15.1
Age Group		
Under 18	0	0.0
18-19	10	13.7
20-24	13	17.8
25-29	17	23.3
30-34	10	13.7
35-39	4	5.5
40-44	6	8.2
45+	13	17.8
Total	*73*	*100*

Table 5: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	*%*
Under 18	0	0.0	0	0.0	*0*	*0.0*
18-19	26	9.4	7	14.0	*33*	*10.1*
20-24	70	25.4	8	16.0	*78*	*23.9*
25-29	46	16.7	14	28.0	*60*	*18.4*
30-34	33	12.0	4	8.0	*37*	*11.3*
35-39	33	12.0	5	10.0	*38*	*11.7*
40-44	25	9.1	6	12.0	*31*	*9.5*
45+	43	15.6	6	12.0	*49*	*15.0*
Total	*276*	*100*	*50*	*100*	*326*	*100*

Table 6: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	1	0
Cannabis	4	1
Crack	5	1
Cocaine	0	1
Ecstasy	0	0
Heroin	6	1
Methadone	2	0
Prescription Drugs	1	1
Solvents	0	1

Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

ASROs
- 0 ASROs commenced during Q4
- 0 Individuals commenced ASROs during Q4
- 4 ASROs were terminated during Q4
- 3 Individuals had their ASROs terminated during Q4

NEEDLE AND SYRINGE PROGRAMMES
Quarter 4 (2009/10)

Introduction

Data are collected directly from NSP providers. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

There has been a disruption to agency NSP data due to inputting errors on the agency needle exchange database resulting in a loss of attributable data. This issue is temporary and is currently being corrected by the agency needle exchange. As a result current quarter and year to date figures are lower comparable to 2008/09. If you have any queries relating to this matter please contact the IAD.

AGENCY NSP

Table 7: Individuals by Gender

New Clients	n	%
Male	23	100.0
Female	0	0.0
Total	23	100
All Clients		
Male	75	96.2
Female	3	3.8
Total	78	100

Table 8: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	5	100.0
Female	0	0.0
Total	5	100
All Clients		
Male	15	83.3
Female	3	16.7
Total	18	100

Table 9: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	4.3	1	1.3
20-24	10	43.5	20	25.6
25-29	5	21.7	20	25.6
30-34	3	13.0	19	24.4
35-39	3	13.0	9	11.5
40-44	0	0.0	4	5.1
45+	1	4.3	5	6.4
Total	23	100	78	100

Table 10: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	0	0.0	4	22.2
25-29	1	20.0	1	5.6
30-34	1	20.0	6	33.3
35-39	2	40.0	3	16.7
40-44	0	0.0	3	16.7
45+	1	20.0	1	5.6
Total	5	100	18	100

Table 11: Gender by Age Group of Individuals

Age Group	Male		Female	
	n	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	1	1.3	0	0.0
20-24	20	26.7	0	0.0
25-29	20	26.7	0	0.0
30-34	17	22.7	2	66.7
35-39	9	12.0	0	0.0
40-44	3	4.0	1	33.3
45+	5	6.7	0	0.0
Total	75	100	3	100

Table 12: Gender by Age Group: Steroid Users omitted

Age Group	Male		Female	
	n	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	4	26.7	0	0.0
25-29	1	6.7	0	0.0
30-34	4	26.7	2	66.7
35-39	3	20.0	0	0.0
40-44	2	13.3	1	33.3
45+	1	6.7	0	0.0
Total	15	100	3	100

Table 13: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	2	1.0	1	5.9	3	1.4
20-24	42	21.3	3	17.6	45	21.0
25-29	56	28.4	3	17.6	59	27.6
30-34	40	20.3	6	35.3	46	21.5
35-39	28	14.2	1	5.9	29	13.6
40-44	22	11.2	2	11.8	24	11.2
45+	7	3.6	1	5.9	8	3.7
Total	197	100	17	100	214	100

Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	0	0.0	1	6.3	1	1.5
20-24	4	8.0	2	12.5	6	9.1
25-29	8	16.0	3	18.8	11	16.7
30-34	9	18.0	6	37.5	15	22.7
35-39	13	26.0	1	6.3	14	21.2
40-44	15	30.0	2	12.5	17	25.8
45+	1	2.0	1	6.3	2	3.0
Total	50	100	16	100	66	100

Table 15: Main Drug of Use for New Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	4	17.4	0	0.0
Methadone	0	0.0	0	0.0
Steroids	18	78.3	0	0.0
Unknown	1	4.3	0	0.0
Total	23	100	0	0

Table 16: Main Drug of Use for All Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	14	18.7	2	66.7
Methadone	0	0.0	1	33.3
Steroids	60	80.0	0	0.0
Various	0	0.0	0	0.0
Unknown	1	1.3	0	0.0
Total	75	100	3	100

Current Quarter; Melanotan Clients
- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0 Male clients reported using melanotan during Q4
- 0 Female clients reported using melanotan during Q4

Table 17: Main Drug of Use for New Agency NSP Clients, by Age Group

Age Group	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	1	5.6
20-24	-	-	-	-	-	-	-	-	0	0.0	-	-	10	55.6
25-29	-	-	-	-	-	-	-	-	1	25.0	-	-	4	22.2
30-34	-	-	-	-	-	-	-	-	1	25.0	-	-	2	11.1
35-39	-	-	-	-	-	-	-	-	1	25.0	-	-	1	5.6
40-44	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
45+	-	-	-	-	-	-	-	-	1	25.0	-	-	0	0.0
Total	-	-	-	-	-	-	-	-	4	100	-	-	18	100

% Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY NSP

Table 18: Individuals by Gender

New Clients	n	%
Male	87	83.7
Female	17	16.3
Total	104	100
All Clients		
Male	239	85.7
Female	40	14.3
Total	279	100

Table 19: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	6	5.8	9	3.2
20-24	23	22.1	50	17.9
25-29	30	28.8	61	21.9
30-34	13	12.5	45	16.1
35-39	16	15.4	57	20.4
40-44	10	9.6	37	13.3
45+	6	5.8	20	7.2
Total	104	100	279	100

Table 20: Main Drug of Use for Pharmacy NSP Clients by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Crack	0	0.0	0	0.0
Heroin	35	14.6	7	17.5
Steroids	19	7.9	1	2.5
Unknown	185	77.4	32	80.0
Total	239	100	40	100

Please Note: Main drug of use is being collected in Warrington pharmacy NSPs from March 2010 - this is currently optional and at present two of the four Warrington pharmacy NSPs are collecting this data

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	<1	0	0.0	3	<1
18-19	26	5.0	0	0.0	26	4.2
20-24	129	24.7	16	17.6	145	23.7
25-29	118	22.6	14	15.4	132	21.5
30-34	69	13.2	19	20.9	88	14.4
35-39	99	19.0	23	25.3	122	19.9
40-44	50	9.6	9	9.9	59	9.6
45+	28	5.4	10	11.0	38	6.2
Total	522	100	91	100	613	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 22: Individuals in NSP, by Gender

New Clients	n	%
Male	108	86.4
Female	17	13.6
Total	125	100
All Clients		
Male	308	88.3
Female	41	11.7
Total	349	100

Table 23: Individuals in NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	80	83.3
Female	16	16.7
Total	96	100
All Clients		
Male	231	85.2
Female	40	14.8
Total	271	100

*Only known steroid users, based on Agency NSP data and Pharmacy NSP Data, have been omitted.

Table 24: Individuals in NSP, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	7	5.6	10	2.9
20-24	32	25.6	68	19.5
25-29	35	28.0	80	22.9
30-34	16	12.8	60	17.2
35-39	19	15.2	66	18.9
40-44	9	7.2	40	11.5
45+	7	5.6	25	7.2
Total	125	100	349	100

Table 25: Individuals in NSP by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	5	5.2	8	3.0
20-24	17	17.7	44	16.2
25-29	26	27.1	53	19.6
30-34	14	14.6	46	17.0
35-39	18	18.8	60	22.1
40-44	9	9.4	39	14.4
45+	7	7.3	21	7.7
Total	96	100	271	100

Table 26: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	<1	0	0.0	3	<1
18-19	28	4.1	1	1.0	29	3.7
20-24	165	24.1	19	19.0	184	23.4
25-29	167	24.4	15	15.0	182	23.2
30-34	104	15.2	22	22.0	126	16.1
35-39	119	17.4	23	23.0	142	18.1
40-44	64	9.3	10	10.0	74	9.4
45+	35	5.1	10	10.0	45	5.7
Total	685	100	100	100	785	100

Table 27: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	7,161	13,642	20,803	64,781

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2009/10)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 28: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	83	84.7
Female	15	15.3
Total	98	100
All Clients		
Male	633	74.8
Female	213	25.2
Total	846	100

Table 29: Year to Date, by Gender

New Clients	n	%
Male	298	78.4
Female	82	21.6
Total	380	100
All Clients		
Male	660	74.0
Female	232	26.0
Total	892	100

Table 30: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	10	10.2	75	8.9
18-19	2	2.0	23	2.7
20-24	12	12.2	89	10.5
25-29	18	18.4	155	18.3
30-34	12	12.2	189	22.3
35-39	24	24.5	173	20.4
40-44	12	12.2	87	10.3
45+	8	8.2	55	6.5
Total	98	100	846	100

Table 31: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	39	10.3	113	12.7
18-19	10	2.6	29	3.3
20-24	44	11.6	90	10.1
25-29	71	18.7	156	17.5
30-34	68	17.9	191	21.4
35-39	70	18.4	173	19.4
40-44	47	12.4	84	9.4
45+	31	8.2	56	6.3
Total	380	100	892	100

Table 32: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	92	93.9	817	96.6
White Irish	0	0.0	6	<1
Other White	2	2.0	6	<1
White & Black Caribbean	2	2.0	4	<1
Other Black	0	0.0	1	<1
African	0	0.0	1	0.0
White & Asian	0	0.0	0	0.0
Other Asian	0	0.0	2	<1
Other Mixed	0	0.0	3	<1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	0	0.0
Other	2	2.0	5	<1
Unknown	0	0.0	1	<1
Total	98	100	846	100

Table 33: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	56	57.1	533	63.0
Methadone	6	6.1	31	3.7
Other Opiates	2	2.0	23	2.7
Benzodiazepine	1	1.0	10	1.2
Amphetamines	4	4.1	18	2.1
Cocaine	13	13.3	93	11.0
Crack	2	2.0	13	1.5
Ecstasy	0	0.0	4	<1
Prescription Drugs	0	0.0	6	<1
Cannabis	14	14.3	107	12.6
Solvents	0	0.0	4	<1
Hallucinogens	0	0.0	1	<1
Other/Unknown	0	0.0	3	<1
Total	*98*	*100*	*846*	*100*

COMBINED DATASETS
Quarter 4 (2009/10)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSP (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 34: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	935	79.2
Female	245	20.8
Age Group		
Under 18	75	6.4
18-19	43	3.6
20-24	168	14.2
25-29	239	20.3
30-34	242	20.5
35-39	212	18.0
40-44	118	10.0
45+	83	7.0
Total	1,180	100

Table 35: Year to Date, by Gender and Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	n	%
Under 18	92	6.3	32	9.5	124	6.9
18-19	75	5.2	18	5.3	93	5.2
20-24	267	18.4	46	13.6	313	17.5
25-29	288	19.8	66	19.5	354	19.8
30-34	251	17.3	74	21.9	325	18.2
35-39	231	15.9	55	16.3	286	16.0
40-44	134	9.2	27	8.0	161	9.0
45+	113	7.8	20	5.9	133	7.4
Total	1,451	100	338	100	1,789	100

CROSS-MATCHED DATASETS
Quarter 4 (2009/10)

Data are shown for the crossover between each type of NSP and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of NSP site.

**Fig 2: Crossover between Agency NSP and NDTMS datasets**

AGENCY (18) — 7 Male 2 Female — NDTMS (846)

Fig 3: Crossover between Pharmacy NSP and NDTMS datasets

PHARMACY (259) — 66 Male 17 Female — NDTMS (846)

**Fig 4: Year to Date Crossover between Agency NSP and NDTMS datasets**

Fig 5: Year to Date Crossover between Pharmacy NSP and NDTMS datasets